(TFX) Teleflex - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8793691069
TFX: Catheters, Pumps, Clippers, Ventilators, Stents, Syringes
Teleflex Incorporated (NYSE: TFX) is a leading global provider of single-use medical devices, primarily serving critical care and surgical applications. Established in 1943 and headquartered in Wayne, Pennsylvania, the company has built a robust portfolio addressing diverse medical needs. Their products are utilized across various healthcare settings, including hospitals, emergency medicine, military, and home care, showcasing their broad market reach.
Their vascular access products, notably the Arrow branded catheters, are integral for administering IV therapies and blood sampling, offering efficient solutions through a single puncture site. This minimizes patient discomfort and streamlines clinical procedures, highlighting their focus on patient-centric innovation.
In the interventional realm, Teleflex offers a range of devices used by cardiologists and surgeons. This includes coronary catheters and structural heart support systems, which are crucial for treating cardiovascular conditions. Their mechanical circulatory support platforms underscore their commitment to advancing cardiac care, providing life-sustaining solutions for critical patients.
The companys anesthesia and surgical products further demonstrate their comprehensive approach. From airway management tools to ligation clips and fascial closure systems, these devices are essential for minimally invasive surgeries, reducing recovery times and enhancing surgical outcomes.
Teleflexs urology segment includes the innovative UroLift System, designed to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. This minimally invasive solution reflects their dedication to improving quality of life for patients with chronic conditions.
With a market capitalization of $7,956.27 billion, Teleflexs financial health is indicated by a P/E ratio of 34.01 and a forward P/E of 10.88, suggesting investor confidence in future growth. Their price-to-book ratio of 1.78 and price-to-sales ratio of 2.63 provide further insight into their valuation metrics, important for investors assessing market position and profitability.
Teleflexs global presence and diverse product offerings position them as a key player in the health care equipment industry, catering to both medical device manufacturers and home care markets. Their commitment to innovation and patient care continues to drive their growth and relevance in the medical field.
Additional Sources for TFX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
TFX Stock Overview
Market Cap in USD | 6,318m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1988-02-18 |
TFX Stock Ratings
Growth 5y | -65.6% |
Fundamental | 14.3% |
Dividend | 33.7% |
Rel. Strength Industry | -39.7 |
Analysts | 3.36/5 |
Fair Price Momentum | 110.37 USD |
Fair Price DCF | 253.82 USD |
TFX Dividends
Dividend Yield 12m | 0.59% |
Yield on Cost 5y | 0.37% |
Annual Growth 5y | 0.00% |
Payout Consistency | 95.4% |
TFX Growth Ratios
Growth Correlation 3m | -68.3% |
Growth Correlation 12m | -52.2% |
Growth Correlation 5y | -83.3% |
CAGR 5y | -13.19% |
CAGR/Max DD 5y | -0.19 |
Sharpe Ratio 12m | -0.49 |
Alpha | -45.40 |
Beta | 0.27 |
Volatility | 46.04% |
Current Volume | 1034.2k |
Average Volume 20d | 850.6k |
As of March 13, 2025, the stock is trading at USD 135.52 with a total of 1,034,203 shares traded.
Over the past week, the price has changed by +1.26%, over one month by -19.29%, over three months by -25.89% and over the past year by -39.74%.
Neither. Based on ValueRay Fundamental Analyses, Teleflex is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 14.28 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of TFX as of March 2025 is 110.37. This means that TFX is currently overvalued and has a potential downside of -18.56%.
Teleflex has received a consensus analysts rating of 3.36. Therefor, it is recommend to hold TFX.
- Strong Buy: 0
- Buy: 5
- Hold: 9
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, TFX Teleflex will be worth about 119.2 in March 2026. The stock is currently trading at 135.52. This means that the stock has a potential downside of -12.01%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 168.2 | 24.1% |
Analysts Target Price | 238.7 | 76.1% |
ValueRay Target Price | 119.2 | -12% |